LHKOREA12

<p><a href="https://www.thebionews.net/news/articleView.html?idxno=2716" target="_top" class="ke-link">삼성바이오에피스, '솔리리스 바이오시밀러' 국내 최초 허가 < 희귀질환 < 기사본문 - 더바이오 (thebionews.net)</a></p><div class="figure-open" contenteditable="false" data-ke-type="opengraph" data-ke-align="alignCenter" data-og-type="website" data-og-title="삼성바이오에피스, '솔리리스 바이오시밀러' 국내 최초 허가" data-og-description="[더바이오 이영성 기자] 삼성바이오에피스는 지난 19일 식품의약품안전처로부터 혈액학 분야 난치성 희귀질환 치료제 '솔리리스(Soliris)'의 바이오시밀러 '에피스클리(프로젝트명 SB12, 성분명 에" data-og-host="www.thebionews.net" data-og-source-url="https://www.thebionews.net/news/articleView.html?idxno=2716" data-og-url="https://www.thebionews.net/news/articleView.html?idxno=2716" data-og-image="https://scrap.kakaocdn.net/dn/bt2G4h/hyU85L3Vtf/IkjgKXragYzBDCD7TykYWK/img.jpg?width=960&height=640&face=0_0_960_640,https://scrap.kakaocdn.net/dn/j6nvn/hyU829CVyC/LehGiTDKfRb0Sh5YIJSEW1/img.jpg?width=960&height=640&face=0_0_960_640,https://scrap.kakaocdn.net/dn/pWZyh/hyU84fjtBx/LCsN8ZXpHlZrBOcZ8oJFtK/img.jpg?width=960&height=640&face=0_0_960_640"><a href="https://www.thebionews.net/news/articleView.html?idxno=2716" target="_blank" data-source-url="https://www.thebionews.net/news/articleView.html?idxno=2716"><div class="og-image"><img src="https://scrap.kakaocdn.net/dn/bt2G4h/hyU85L3Vtf/IkjgKXragYzBDCD7TykYWK/img.jpg?width=960&height=640&face=0_0_960_640,https://scrap.kakaocdn.net/dn/j6nvn/hyU829CVyC/LehGiTDKfRb0Sh5YIJSEW1/img.jpg?width=960&height=640&face=0_0_960_640,https://scrap.kakaocdn.net/dn/pWZyh/hyU84fjtBx/LCsN8ZXpHlZrBOcZ8oJFtK/img.jpg?width=960&height=640&face=0_0_960_640" alt="" xxonerror="this.src="//img1.kakaocdn.net/thumb/C200x200/?fname=https%3A%2F%2Ft1.daumcdn.net%2Fcafe_image%2Fcafe_meta_image_190529.png""></div><div class="og-text"><p class="og-title">삼성바이오에피스, '솔리리스 바이오시밀러' 국내 최초 허가</p><p class="og-desc">[더바이오 이영성 기자] 삼성바이오에피스는 지난 19일 식품의약품안전처로부터 혈액학 분야 난치성 희귀질환 치료제 '솔리리스(Soliris)'의 바이오시밀러 '에피스클리(프로젝트명 SB12, 성분명 에</p><p class="og-host">www.thebionews.net</p></div></a></div><p> </p>